• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Phathom Pharmaceuticals, Inc. - Common Stock (NQ:PHAT)

    13.54 -0.64 (-4.55%)
    Streaming Delayed Price Updated: 12:13 PM EST, Jan 23, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Phathom Pharmaceuticals, Inc. - Common Stock

    < Previous 1 2 3 4 5 6 7 8 9 Next >
    News headline image
    Phathom Pharma Shows Sales Strength, Targets 2026 Profitability ↗
    Phathom Pharmaceuticals (NASDAQ: PHAT) reported Q4 sales of $57-$58 million, updated FY2025 revenue guidance to $174.5-$175.5 million. 
    Via Benzinga
    Get insights into the top gainers and losers of Thursday's pre-market session. ↗
    Via Chartmill
    News headline image
    Phathom Pharmaceuticals Announces Pricing of $130 Million Public Offering of Common Stock and Pre-Funded Warrants
    From Phathom Pharmaceuticals
    Via GlobeNewswire
    News headline image
    Earnings Scheduled For October 30, 2025 ↗
     
    Via Benzinga
    News headline image
    Earnings Scheduled For August 7, 2025 ↗
     
    Via Benzinga
    Stay updated with the stocks that are on the move in today's after-hours session. ↗
    Via Chartmill
    News headline image
    Phathom Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
    From Phathom Pharmaceuticals
    Via GlobeNewswire
    News headline image
    Phathom Pharmaceuticals Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results
    From Phathom Pharmaceuticals
    Via GlobeNewswire
    News headline image
    PHATHOM PHARMACEUTICALS INC (NASDAQ:PHAT) Shows Strong Growth and Momentum Alignment with Minervini Strategy ↗
    PHAT stock aligns with the Minervini growth strategy, showing a strong technical uptrend and explosive 460% revenue growth, making it a high-potential momentum candidate. 
    Via Chartmill
    News headline image
    High Growth Momentum and Technical Strength Drive PHATHOM PHARMACEUTICALS INC (NASDAQ:PHAT) ↗
    Discover a powerful stock-picking strategy combining Minervini's Trend Template with High Growth Momentum to find high-potential stocks like PHAT. 
    Via Chartmill
    News headline image
    Phathom Pharmaceuticals Announces First Patient Dosed in Phase 2 Study of VOQUEZNA® (vonoprazan) in Eosinophilic Esophagitis (EoE)
    From Phathom Pharmaceuticals
    Via GlobeNewswire
    News headline image
    Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
    From Phathom Pharmaceuticals
    Via GlobeNewswire
    News headline image
    Phathom Pharmaceuticals (NASDAQ:PHAT) Surpasses Q3 2025 Earnings Estimates and Raises Full-Year Guidance ↗
    Phathom Pharma's Q3 2025 earnings beat expectations. Revenue hit $49.5M, and its EPS loss narrowed to $0.15. The company also raised its full-year 2025 revenue guidance. 
    Via Chartmill
    Topics Earnings
    News headline image
    Phathom Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update
    From Phathom Pharmaceuticals
    Via GlobeNewswire
    News headline image
    Phathom Pharmaceuticals Announces Publication of Data from Phase 3 pHalcon-NERD-301 Study Showing VOQUEZNA® (vonoprazan) Improved Nocturnal GERD Symptoms in Patients with Non-Erosive Reflux Disease
    From Phathom Pharmaceuticals
    Via GlobeNewswire
    News headline image
    Phathom Pharmaceuticals to Highlight VOQUEZNA® (vonoprazan) at the American College of Gastroenterology (ACG) 2025 Annual Scientific Meeting
    From Phathom Pharmaceuticals
    Via GlobeNewswire
    News headline image
    Phathom Pharmaceuticals to Report Third Quarter 2025 Financial Results and Provide Business Update on Thursday, October 30, 2025
    From Phathom Pharmaceuticals
    Via GlobeNewswire
    News headline image
    Phathom Pharmaceuticals Appoints Sanjeev Narula as Chief Financial and Business Officer
    From Phathom Pharmaceuticals
    Via GlobeNewswire
    News headline image
    12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
     
    Via Benzinga
    News headline image
    Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
    From Phathom Pharmaceuticals
    Via GlobeNewswire
    News headline image
    Phathom Pharmaceuticals Clarifies That There Is No Reduction in Lead Shareholder’s Ownership Following Administrative Change to 13D Filing
    From Phathom Pharmaceuticals
    Via GlobeNewswire
    News headline image
    Phathom (PHAT) Q2 Revenue Jumps 441% ↗
    Via The Motley Fool
    News headline image
    Phathom Pharmaceuticals (NASDAQ:PHAT) Surpasses Q2 Estimates with Strong VOQUEZNA Growth, Shares Jump 6% in Premarket ↗
    Phathom Pharmaceuticals (PHAT) beats Q2 revenue and EPS estimates, driven by strong VOQUEZNA adoption. Shares rise 6.2% premarket as company narrows losses and raises full-year guidance. 
    Via Chartmill
    News headline image
    Phathom Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Updates
    From Phathom Pharmaceuticals
    Via GlobeNewswire
    News headline image
    Phathom Pharmaceuticals to Report Second Quarter 2025 Financial Results and Provide Business Update on Thursday, August 7, 2025
    From Phathom Pharmaceuticals
    Via GlobeNewswire
    News headline image
    Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Phathom Pharmaceuticals
    Via GlobeNewswire
    News headline image
    Phathom Pharmaceuticals Appoints Anne Marie Cook as Chief Legal Officer and Corporate Secretary
    From Phathom Pharmaceuticals
    Via GlobeNewswire
    News headline image
    Phathom Pharmaceuticals Announces FDA Correction to Orange Book Listing, Confirming 10 Years of Regulatory Exclusivity for VOQUEZNA® (vonoprazan) Tablets Through May 3, 2032
    From Phathom Pharmaceuticals
    Via GlobeNewswire
    News headline image
    Unusual Machines, Celldex Therapeutics, RH And Other Big Stocks Moving Higher On Friday ↗
     
    Via Benzinga
    News headline image
    Phathom Pharmaceuticals Stock Doubles After FDA Grants Full 10-Year Exclusivity For Voquezna ↗
    Phathom Pharmaceuticals Inc. (NASDAQ: PHAT) shares are trading lower Friday after the company announced a major regulatory win. 
    Via Benzinga
    < Previous 1 2 3 4 5 6 7 8 9 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.